New combo therapies aim to control advanced lung cancer

NCT ID NCT03381274

Ongoing Disease control Sponsor: MedImmune LLC Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 25 times

Summary

This study tests new drug combinations in 43 adults with advanced EGFR-mutant non-small cell lung cancer that has been treated before. The goal is to see if these combinations are safe and can shrink tumors. Participants receive one of several experimental drug pairs, and researchers monitor side effects and cancer response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

San Francisco, California, 94143, United States
Research Site

Aurora, Colorado, 80045, United States
Research Site

New Haven, Connecticut, 06510, United States
Research Site

Atlanta, Georgia, 30322, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Baltimore, Maryland, 21224, United States
Research Site

New York, New York, 10032, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Taichung, 40705, Taiwan

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG